Cyclopharms Technegas Gains Traction in the U.S. Market

Cyclopharm Limited (ASX: CYC), a leading Australian radiopharmaceutical company, has achieved a major milestone with over US$1 million in sales of its flagship product, Technegas®, in the United States. This reflects strong adoption by key medical institutions and growing clinical recognition. Technegas®, used primarily for lung ventilation imaging, is now installed in 27 U.S. sites, up from 17 in late 2024, and has become the fourth-largest revenue contributor among the 66 countries where it is available. The company anticipates the U.S. will become its top market by the end of 2025. Supported by FDA approval, federal and private sector contracts, and established reimbursement systems, Technegas® is expanding into broader applications like COPD and asthma. Cyclopharm is also planning a local manufacturing facility to enhance supply resilience. CEO James McBrayer highlighted these developments as a foundation for sustainable growth and recurring revenue generation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com